In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Dare Bioscience Inc’s stock clocked out at $2.17, up 0.46% from its previous closing price of $2.16. In other words, the price has increased by $0.46 from its previous closing price. On the day, 94034.0 shares were traded. DARE stock price reached its highest trading level at $2.18 during the session, while it also had its lowest trading level at $2.1.
Ratios:
To gain a deeper understanding of DARE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.18 and its Current Ratio is at 1.18. In the meantime, Its Debt-to-Equity ratio is 2.85 whereas as Long-Term Debt/Eq ratio is at 1.98.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DARE now has a Market Capitalization of 29250520 and an Enterprise Value of 10864912. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.49 while its Price-to-Book (P/B) ratio in mrq is 10.58. Its current Enterprise Value per Revenue stands at -190.179 whereas that against EBITDA is -0.664.
Stock Price History:
The Beta on a monthly basis for DARE is 0.79, which has changed by -0.34545457 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, DARE has reached a high of $9.19, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is 10.86%, while the 200-Day Moving Average is calculated to be -10.59%.
Shares Statistics:
It appears that DARE traded 196.41K shares on average per day over the past three months and 520920 shares per day over the past ten days. A total of 13.93M shares are outstanding, with a floating share count of 12.78M. Insiders hold about 10.57% of the company’s shares, while institutions hold 7.06% stake in the company. Shares short for DARE as of 1764288000 were 192561 with a Short Ratio of 2.37, compared to 1761868800 on 221779. Therefore, it implies a Short% of Shares Outstanding of 192561 and a Short% of Float of 1.3599999999999999.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Dare Bioscience Inc (DARE) in the stock market.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.48 and -$1.86 for the fiscal current year, implying an average EPS of -$1.65. EPS for the following year is -$0.35, with 3.0 analysts recommending between $1.23 and -$1.69.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $765k. It ranges from a high estimate of $1.43M to a low estimate of $103k. As of. The current estimate, Dare Bioscience Inc’s year-ago sales were -$63.65kFor the next quarter, 2 analysts are estimating revenue of $1.57M. There is a high estimate of $2.9M for the next quarter, whereas the lowest estimate is $250k.
A total of 2 analysts have provided revenue estimates for DARE’s current fiscal year. The highest revenue estimate was $1.43M, while the lowest revenue estimate was $109k, resulting in an average revenue estimate of $771k. In the same quarter a year ago, actual revenue was $9.78kBased on 3 analysts’ estimates, the company’s revenue will be $22.55M in the next fiscal year. The high estimate is $56.58M and the low estimate is $1.09M.
